In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?
In a bold move to reduce U.S. prescription drug prices, AstraZeneca and Pfizer have struck deals with the White House, promising significant discounts for patients. This comes amid rising pressure from President Trump on drugmakers to lower costs or face hefty tariffs. Will these changes truly benefit American patients?
Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
President Trump reveals plans for a new website, TrumpRx, aimed at providing discounted prescription medications directly to Americans, particularly benefiting low-income families. This initiative follows Pfizer's agreement to lower drug prices, promising a transformative approach to healthcare access.
President Trump announces major changes to prescription drug pricing, with Pfizer leading the way. Discover how U.S. patients will benefit from this new initiative and what it means for the future of healthcare.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
Pharma faces a daunting challenge as Trump takes bold steps to cut drug prices. With RFK Jr. praising the move, is bipartisanship on the horizon or will the industry fight back?
In a groundbreaking move, President Trump has issued an executive order aimed at ending the price discrimination faced by American consumers in the pharmaceutical market. This order seeks to ensure that Americans pay the same low prices for medications as those in other developed nations, addressing the long-standing issue of subsidizing global pharmaceutical profits.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
President Trump is set to sign an executive order aiming to lower drug prices in the US by aligning them with prices in wealthy nations. This 'most favored nation' model could face legal challenges.
